Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference Transcript

At the Jefferies Global Healthcare Conference, Moderna's President Stephen Hoge reaffirmed the company's revenue and cost guidance for 2025, as initially provided at the beginning of the year. Hoge highlighted progress with the next-generation COVID vaccine approval, mRNA-1283. He also addressed concerns regarding the potential impact of administrative changes on Moderna's business and its ability to meet financial targets for the year.

Analysis

Moderna's President, Stephen Hoge, speaking at the Jefferies Global Healthcare Conference on June 5, 2025, reaffirmed the company's existing revenue and cost guidance for the year 2025, as initially stated at the beginning of the year and reiterated in the recent quarterly call. This reaffirmation offers a degree of stability to the company's financial outlook, with a reported mildly positive sentiment (MRNA ticker sentiment: 0.6) surrounding these communications. Hoge also highlighted ongoing progress concerning the approval process for its next-generation COVID vaccine, mRNA-1283, signaling a potential catalyst for future performance. The discussion further acknowledged and addressed investor concerns regarding the potential impact of unspecified "administrative changes" on Moderna's business operations and its capacity to achieve stated financial targets for the current year, indicating the company's awareness of these external variables.

Key Decisions for Investors

• Investors should continue to monitor Moderna's execution against its reaffirmed 2025 revenue and cost guidance in subsequent financial disclosures.
• The regulatory pathway and potential market launch of the next-generation COVID vaccine, mRNA-1283, warrant close observation due to its potential impact on future revenue.
• Investors should remain vigilant regarding any "administrative changes" and assess their potential implications for Moderna's commercial activities and financial performance.